No Result
View All Result
SUBMIT YOUR ARTICLES
  • Login
Sunday, December 28, 2025
TheAdviserMagazine.com
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal
No Result
View All Result
TheAdviserMagazine.com
No Result
View All Result
Home Market Research Business

US vaccine advisers end decades-long recommendation for all babies to get hepatitis B shot at birth

by TheAdviserMagazine
3 weeks ago
in Business
Reading Time: 5 mins read
A A
US vaccine advisers end decades-long recommendation for all babies to get hepatitis B shot at birth
Share on FacebookShare on TwitterShare on LInkedIn



A federal vaccine advisory committee voted on Friday to end the longstanding recommendation that all U.S. babies get the hepatitis B vaccine on the day they’re born.

A loud chorus of medical and public health leaders decried the actions of the panel, whose current members were all appointed by U.S. Health Secretary Robert F. Kennedy Jr. — a leading anti-vaccine activist before this year becoming the nation’s top health official.

“This is the group that can’t shoot straight,” said Dr. William Schaffner, a Vanderbilt University vaccine expert who for decades has been involved with the Advisory Committee on Immunization Practices and its workgroups.

Several medical societies and state health departments said they would continue to recommend them. While people may have to check their policies, the trade group AHIP, formerly known as America’s Health Insurance Plans, said its members still will cover the birth dose of the hepatitis B vaccine.

For decades, the government has advised that all babies be vaccinated against the liver infection right after birth. The shots are widely considered to be a public health success for preventing thousands of illnesses.

But Kennedy’s advisory committee decided to recommend the birth dose only for babies whose mothers test positive, and in cases where the mom wasn’t tested.

For other babies, it will be up to the parents and their doctors to decide if a birth dose is appropriate. The committee voted 8-3 to suggest that when a family elects to wait, then the vaccination series should begin when the child is 2 months old.

President Donald Trump posted a message late Friday calling the vote a “very good decision.”

The acting director of the Centers for Disease Control and Prevention, Jim O’Neill, is expected to decide later whether to accept the committee’s recommendation.

The decision marks a return to a health strategy abandoned more than three decades ago

Asked why the newly-appointed committee moved quickly to reexamine the recommendation, committee member Vicky Pebsworth on Thursday cited “pressure from stakeholder groups,” without naming them.

Committee members said the risk of infection for most babies is very low and that earlier research that found the shots were safe for infants was inadequate.

They also worried that in many cases, doctors and nurses don’t have full conversations with parents about the pros and cons of the birth-dose vaccination.

The committee members voiced interest in hearing the input from public health and medical professionals, but chose to ignore the experts’ repeated pleas to leave the recommendations alone.

The committee gives advice to the director of the Centers for Disease Control and Prevention on how approved vaccines should be used. CDC directors almost always adopted the committee’s recommendations, which were widely heeded by doctors and guide vaccination programs. But the agency currently has no director, leaving acting director O’Neill to decide.

In June, Kennedy fired the entire 17-member panel earlier this year and replaced it with a group that includes several anti-vaccine voices.

Hepatitis B and delaying birth doses

Hepatitis B is a serious liver infection that, for most people, lasts less than six months. But for some, especially infants and children, it can become a long-lasting problem that can lead to liver failure, liver cancer and scarring called cirrhosis.

In adults, the virus is spread through sex or through sharing needles during injection drug use. But it can also be passed from an infected mother to a baby.

In 1991, the committee recommended an initial dose of hepatitis B vaccine at birth. Experts say quick immunization is crucial to prevent infection from taking root. And, indeed, cases in children have plummeted.

Still, several members of Kennedy’s committee voiced discomfort with vaccinating all newborns. They argued that past safety studies of the vaccine in newborns were limited and it’s possible that larger, long-term studies could uncover a problem with the birth dose.

But two members said they saw no documented evidence of harm from the birth doses and suggested concern was based on speculation.

Three panel members asked about the scientific basis for saying that the first dose could be delayed for two months for many babies.

“This is unconscionable,” said committee member Dr. Joseph Hibbeln, who repeatedly voiced opposition to the proposal during the sometimes-heated two-day meeting.

The committee’s chair, Dr. Kirk Milhoan, said two months was chosen as a point where infants had matured beyond the neonatal stage. Hibbeln countered that there was no data presented that two months is an appropriate cut-off.

Dr. Cody Meissner also questioned a second proposal — which passed 6-4 — that said parents consider talking to pediatricians about blood tests meant to measure whether hep B shots have created protective antibodies.

Such testing is not standard pediatric practice after vaccination. Proponents said it could be a new way to see if fewer shots are adequate.

A CDC hepatitis expert, Adam Langer, said results could vary from child to child and would be an erratic way to assess if fewer doses work. He also noted there’s no good evidence that three shots pose harm to kids.

Meissner attacked the proposal, saying the language “is kind of making things up.”

Health experts say this could ‘make America sicker’

Health experts have noted Kennedy’s hand-picked committee is focused on the pros and cons of shots for the individual getting vaccinated, and has turned away from seeing vaccinations as a way to stop the spread of preventable diseases among the public.

The second proposal “is right at the center of this paradox,” said committee member Dr. Robert Malone.

Some observers criticized the meeting, noting recent changes in how they are conducted. CDC scientists no longer present vaccine safety and effectiveness data to the committee. Instead, people who have been prominent voices in anti-vaccine circles were given those slots.

The committee “is no longer a legitimate scientific body,” said Elizabeth Jacobs, a member of Defend Public Health, an advocacy group of researchers and others that has opposed Trump administration health policies. She described the meeting this week as “an epidemiological crime scene.”

Republican Sen. Bill Cassidy, a liver doctor who chairs the Senate health committee, called the committee’s vote on the hepatitis B vaccine “a mistake.”

“This makes America sicker,” he said, in a post on social media.

The committee heard a 90-minute presentation from Aaron Siri, a lawyer who has worked with Kennedy on vaccine litigation. He ended by saying that he believes there should no ACIP vaccine recommendations at all.

In a lengthy response, Meissner said, “What you have said is a terrible, terrible distortion of all the facts.” He ended by saying Siri should not have been invited.

The meeting’s organizers said they invited Siri as well as a few vaccine researchers — who have been vocal defenders of immunizations — to discuss the vaccine schedule. They named two: Dr. Peter Hotez, who said he declined, and Dr. Paul Offit, who said he didn’t remember being asked but would have declined anyway.

Hotez, of the Texas Children’s Hospital in Houston, declined to present before the group “because ACIP appears to have shifted its mission away from science and evidence-based medicine,” he said in an email to The Associated Press.



Source link

Tags: advisersBabiesbirthdecadeslonghepatitisrecommendationshotVaccine
ShareTweetShare
Previous Post

Ripple CTO Joins Debate On Bitcoin Versus Gold, Says Bitcoin Cannot Be Replicated

Next Post

Pharmacies Are Changing Refill Schedules for High-Demand Medications

Related Posts

edit post
An Ondas Holdings (ONDS) Insider Sold 29,000 Shares for 1,000

An Ondas Holdings (ONDS) Insider Sold 29,000 Shares for $281,000

by TheAdviserMagazine
December 28, 2025
0

29,698 shares were sold for a total of $281,537.04 on Dec. 22, 2025, at a price of $9.48 per share....

edit post
Survey: 2025 record year for M&A activity in Israel

Survey: 2025 record year for M&A activity in Israel

by TheAdviserMagazine
December 28, 2025
0

More than 300 venture capital partners, angel investors, serial entrepreneurs, and innovation leaders gathered for the annual "Trends &...

edit post
The retirement of this notoriously finicky card marks the end of an era for one of the world’s oldest and largest transit systems

The retirement of this notoriously finicky card marks the end of an era for one of the world’s oldest and largest transit systems

by TheAdviserMagazine
December 28, 2025
0

When the MetroCard replaced the New York City subway token in 1994, the swipeable plastic card infused much-needed modernity into one of...

edit post
Guggenheim Bullish on Abivax (ABVX) Ahead of Key Obefazimod Data Readout

Guggenheim Bullish on Abivax (ABVX) Ahead of Key Obefazimod Data Readout

by TheAdviserMagazine
December 28, 2025
0

ABIVAX Société Anonyme (NASDAQ:ABVX) is one of the best emerging technology stocks to invest in. On December 18, Guggenheim analyst...

edit post
Iron Beam laser defense system delivered to IDF

Iron Beam laser defense system delivered to IDF

by TheAdviserMagazine
December 28, 2025
0

After a complex development process, Israel’s Ministry of Defense Directorate of Defense R&D (DDR&D) (MAFAT) and Rafael Advanced Defense...

edit post
Inside MacKenzie Scott’s close relationship with Toni Morrison

Inside MacKenzie Scott’s close relationship with Toni Morrison

by TheAdviserMagazine
December 28, 2025
0

Before MacKenzie Scott published her first novel or helped shape Amazon in its early days as an online book seller,...

Next Post
edit post
Pharmacies Are Changing Refill Schedules for High-Demand Medications

Pharmacies Are Changing Refill Schedules for High-Demand Medications

edit post
8 Digital Wallet Rule Changes Slowing Down Senior Refunds

8 Digital Wallet Rule Changes Slowing Down Senior Refunds

  • Trending
  • Comments
  • Latest
edit post
How Long is a Last Will and Testament Valid in North Carolina?

How Long is a Last Will and Testament Valid in North Carolina?

December 8, 2025
edit post
In an Ohio Suburb, Sprawl Is Being Transformed Into Walkable Neighborhoods

In an Ohio Suburb, Sprawl Is Being Transformed Into Walkable Neighborhoods

December 14, 2025
edit post
Democrats Insist On Taxing Tips        

Democrats Insist On Taxing Tips        

December 15, 2025
edit post
Detroit Seniors Are Facing Earlier Shutoff Notices This Season

Detroit Seniors Are Facing Earlier Shutoff Notices This Season

December 20, 2025
edit post
Elon Musk adds to his 9 billion fortune after Delaware court awards him  billion pay package

Elon Musk adds to his $679 billion fortune after Delaware court awards him $55 billion pay package

December 20, 2025
edit post
Living Trusts in NC Explained: What You Should Know

Living Trusts in NC Explained: What You Should Know

December 16, 2025
edit post
Survey: 2025 record year for M&A activity in Israel

Survey: 2025 record year for M&A activity in Israel

0
edit post
An Ondas Holdings (ONDS) Insider Sold 29,000 Shares for 1,000

An Ondas Holdings (ONDS) Insider Sold 29,000 Shares for $281,000

0
edit post
14 Penny stocks surged up to 440% in CY25; 6 emerge as multibaggers. Did you own any? – Buyer Beware

14 Penny stocks surged up to 440% in CY25; 6 emerge as multibaggers. Did you own any? – Buyer Beware

0
edit post
The Sunday Morning Movie Presents: Sholay (1975) Run Time: 3H 10M Bonus Cinema Documentary

The Sunday Morning Movie Presents: Sholay (1975) Run Time: 3H 10M Bonus Cinema Documentary

0
edit post
2025 Wealth Management Outlook: Spotlight on Investment Careers

2025 Wealth Management Outlook: Spotlight on Investment Careers

0
edit post
Analyst Says XRP Price On The Verge Of Bearish Breakdown

Analyst Says XRP Price On The Verge Of Bearish Breakdown

0
edit post
An Ondas Holdings (ONDS) Insider Sold 29,000 Shares for 1,000

An Ondas Holdings (ONDS) Insider Sold 29,000 Shares for $281,000

December 28, 2025
edit post
Your Property Value Could Drop If You Ignore This Simple Repair

Your Property Value Could Drop If You Ignore This Simple Repair

December 28, 2025
edit post
Analyst Says XRP Price On The Verge Of Bearish Breakdown

Analyst Says XRP Price On The Verge Of Bearish Breakdown

December 28, 2025
edit post
Survey: 2025 record year for M&A activity in Israel

Survey: 2025 record year for M&A activity in Israel

December 28, 2025
edit post
The retirement of this notoriously finicky card marks the end of an era for one of the world’s oldest and largest transit systems

The retirement of this notoriously finicky card marks the end of an era for one of the world’s oldest and largest transit systems

December 28, 2025
edit post
The 42 Books I Read in 2025

The 42 Books I Read in 2025

December 28, 2025
The Adviser Magazine

The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.

CATEGORIES

  • 401k Plans
  • Business
  • College
  • Cryptocurrency
  • Economy
  • Estate Plans
  • Financial Planning
  • Investing
  • IRS & Taxes
  • Legal
  • Market Analysis
  • Markets
  • Medicare
  • Money
  • Personal Finance
  • Social Security
  • Startups
  • Stock Market
  • Trading

LATEST UPDATES

  • An Ondas Holdings (ONDS) Insider Sold 29,000 Shares for $281,000
  • Your Property Value Could Drop If You Ignore This Simple Repair
  • Analyst Says XRP Price On The Verge Of Bearish Breakdown
  • Our Great Privacy Policy
  • Terms of Use, Legal Notices & Disclosures
  • Contact us
  • About Us

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.